A post hoc CANVAS analysis found no clear kidney or cardiovascular advantage for canagliflozin 300 mg over 100 mg, but the findings are hypothesis-generating rather than definitive.
A new FLOW analysis reports that semaglutide kidney and all-cause death benefits were consistent across cardiovascular-risk groups in adults with type 2 diabetes and chronic kidney disease.
